Melanoma patient
Case report of a <em>KIT</em>-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy
... a melanoma patient with KIT mutation in exon 11, who had progressed after the second-line ...acral melanoma for KIT mutation may open up new treat- ment choice for those ...metastatic melanoma ...
5
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
... To date, the molecular basis and mechanisms of action of ipilimumab have not been documented systematically in vivo. There is a critical need for biomarkers of the effects of ipilimumab as well as potential predictive ...
12
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
... In patients with metastatic disease, a significant fraction of tumor-antigen specific effector and memory T-cells may be detectable in the tumor and peripheral circulation, yet may be constrained by tumor-induced immune ...
8
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
... lignant melanoma of her left upper extremity 10 months prior, in March ...The patient had undergone a complete surgical resection with sentinel lymph node bi- opsy, which showed melanoma with a ...
7
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab
... the patient noted an improved energy level and increased appetite but still was experiencing ...the patient reported sudden onset of bilateral hearing loss and was referred to otology for an ...The ...
6
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report
... The occurrence of LM has to be considered as a possible event during treatment with BRAFi in patients with mel- anoma. Although further studies based on more appropri- ate samplings from patients with meningeal ...
5
Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma
... Impact of HAdV-5-specific cellular memory responses Because most individuals have been previously exposed to HAdV-5 in the environment, we expected that donors and patients would have variable but detectable levels of ...
11
Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth
... human melanoma cell lines and in melanoma patient– derived xenograft (PDX) mouse models, antisense oligonucleotide–mediated (ASO-mediated) skipping of exon 6 decreased MDM4 abundance, inhibited ...
18
Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study
... of melanoma patient perspectives on ...of melanoma drugs in practice conventionally requires longitudinal data collection on ...of patient and carers´ perspectives on HRQoL was performed ...
12
Inhibition of Pannexin 1 reduces tumorigenic properties of human melanoma
... Although melanoma accounts for only 5% of all skin cancers, it is a highly aggressive disease that is responsible for more than 75% of skin cancer deaths [22, ...primary melanoma tumour develops from the ...
103
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone
... Conclusions: This is the first report to our knowledge of disease response to immune checkpoint inhibition in a patient with myelophthisis. Clinical trials have recently emerged describing the efficacy of PD-1 ...
5
Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma
... I–III melanoma; however, patient numbers in these stud- ies were small and have yet to be confirmed in larger cohorts [6, ...identify melanoma patients at high risk of both distant metastatic relapse ...
8
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
... metastatic melanoma correlates positively with increased frequencies of CD163 + (a marker for M2- polarization) macrophages compared to primary melanoma ...of melanoma patients reported by the Human ...
5
Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
... anal melanoma to enable surgi- cal resection with organ and function-sparing effect while a second case described ECT of a digital chondrosarcoma to avoid finger amputation ...metastatic melanoma nodule in ...
5
Employing patient-reported outcome (PRO) measures to support newly diagnosed patients with melanoma : feasibility and acceptability of a holistic needs assessment intervention
... and patient-centred activity that allowed her to get more detailed information about patients’ experiences, prepare herself to respond rather than “react” to expressed needs, and tailor support to tackle these ...
26
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report
... Programmed cell death protein 1 (PD-1) immune check- point inhibitors have been shown to significantly im- prove overall survival among patients with many solid malignancies, in particular patients with metastatic ...
5
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
... In August 2012, an enlargement of surgical margins and sentinel lymph node research were performed; one right and one left axillary lymph node were removed, and were negative for melanoma metastases. Stadiative ...
5
Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
... of Melanoma using PD-L1 Isoforms (#20160340407) pending, a pa- tent Therapeutic peptides (#20160046716) pending, a patent Therapeutic Peptides (#20140004112) pending, a patent Therapeutic Peptides (#20170022275) ...
7
Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto’s disease and diabetes mellitus: a case report
... our patient was treated with amio- darone for 1 year prior to the initiation of nivolumab and ...the patient was admitted to our hospital. Our patient had thyroid function testing that was within ...
5
Morphologically and immunohistochemically undifferentiated gastric neoplasia in a patient with multiple metastatic malignant melanomas: a case report
... The overall median survival time in patients with meta- static melanoma is 7.5 months with a 5-year survival rate of 6%. Patients with GIT metastases have a median sur- vival time of 12.5 months with a 5-year ...
5